Suleyman Eralp "Al" Bellibas, Md, Phd, Faha. Email & Phone Number

East Hanover, NJ, US

Novartis representative for Clinical Pharmacology Leadership Group in IQ Consortium

Basel, Baselstadt, CH

Medical Leadership role within NIBR Translational Medicine supporting clinical pharmacology projects across therapeutic areas including immunology, neuroscience, cardiovascular, musculoskeletal, infectious diseases and oncology early development.

Drug development consulting services to multiple clients in a range of startups to clinical-stage public pharmaceutical/biotech companies. Services include IND-enabling studies, IND filing, Clinical Pharmacology gap analysis, First in Human Dose calculation, study design, protocol writing, Phase 1, Phase 2 POC study design and Phase 3 program management.

Austin, Texas, US

Chief Scientific Advisor role at global scale focused on Clinical Pharmacology and early phases of drug development including Pre-IND/ IND filing activities, medical monitoring and regulatory interactions.

Cambridge, MA, US

Lead Clinical Pharmacology role to support development programs focused on the sGC-NO pathway targeting CNS, Hematology, and Vascular indications including rare/orphan diseases.

Lexington, MA, US

A contract role to conduct Clinical Pharmacology gap analysis and contribute IND filing and clinical study design related activities for an asset in cardiovascular indication.

Durham, North Carolina, US

As an industry thought leader, Clinical Pharmacology and Therapeutic Area Consulting including supporting the Business Development, and Scientific Services functions of the PAREXEL Worldwide Early Phase Group and US and European operations including London, Berlin, Baltimore, and Los Angeles Early Phase clinical units. Also, responsible for providing.

East Hanover, NJ, US

Clinical Pharmacology Head and Member for the DLT (Development Leadership Team), supporting entire clinical development portfolio. Contributing one IND, one Phase I, one Phase II, 2 Phase III and 1 Phase IV potential game changer projects in Cardiovascular and Infectious Disease Therapeutic areas:*ApoAI-Milano*Oritavancin*Oritavancin.

East Hanover, NJ, US

Clinical Pharmacology Head and Members for the DLT (Development Leadership Team) and Safety Management Team (SMT), supporting entire clinical development portfolio.

New York, New York, US

Global Clinical Pharmacology support for Established Products Business Unit (review and update product core data sheets/labels, local registration support, product differentiation strategies, bioequivalence study design and analysis).

Basel, Baselstadt, CH

Translational Medicine leadership role for entire neuroscience pipeline and CNS products in the market. Worked in Exelon Patch team to get NDA approval and provided clinical pharmacology support for regulatory meetings with FDA and international health authorities (EMEA, Canada, RoW). Prepared IND safety updates for CNS portfolio (Clozaril/Leponex.

New Brunswick, NJ, US

Reporting to VP of Clinical Research, built and managed clinical pharmacology department. Responsible for early pipeline development and new transdermal formulation for Natrecor, congestive heart failure treatment. Supervised population PK activities aiming to reduce variability in response and improve safety with optimum individual dosing. Served in Drug.

Switzerland 🇨🇭, CH

Clinical Pharmacologist role for assigned projects. Study design, PK/PD analysis, report writing and safety review on compounds under development for dose escalation or go/no-go decisions. Contributed development of first in-class HIV fusion inhibitor drug Fuzeon. NDA approval was obtained for adult and pediatric indication in less than 2 years of.

Rahway, New Jersey, US

MSD Clinical Pharmacology International Fellowship at UCSF

Aydın, TR

Teaching pharmacology to medical and health sciences students, served in ADU hospital formulary board, PK studies and clinical trials.

Msd International Fellow, Postdoc, Clinical Pharmacology

Fellow, Medical Pharmacology

Phd Eq., Medical Pharmacology

New Trends In Pharmacokinetics; Pharmacovigilance

Doctor Of Medicine (M.D.), Medicine